Arcturus Therapeutics Holdings (ARCT)
(Real Time Quote from BATS)
$19.20 USD
+0.47 (2.51%)
Updated Aug 8, 2024 01:46 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
Brokerage Reports
Arcturus Therapeutics Holdings Inc. [ARCT]
Reports for Purchase
Showing records 81 - 100 ( 141 total )
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Impressive Preclinical Results; Adding COVID-19 Vaccine to Model; Raise PT to $62
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Lead Drug ARCT-810 to Enter Dual Phase 1 Trials in OTC; Raise PT to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
LUNAR Is on Fire with U.S. IND Acceptance for ARCT-810
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Deep Dive into LUNAR-COVID19 - Our Must Read Report
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Coronavirus Vol. 22 All Your COVID Questions Answered by a Top Doc
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Yas'' Weekly Recap of Our Key Notes and 20 Doc Calls Upcoming in 2Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Dial in to Part 2 of Our COVID-19 Drug Developer Call Series Today at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Dial in to Part 1 of Our COVID-19 Drug Developer Call Series Today at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Dial in to Parts 1-2 of Our COVID-19 Drug Developer Series on Apr. 1 - Apr. 2
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Reports Positive Pivotal Interim Results with VB-111 in Ovarian Cancer
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
17 Doc Calls Across 9 Therapeutic Areas Upcoming in 2Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Meet Our COVID-19 Drug Developers Call Series
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Yas'' Weekly Recap of Our Key Notes and 19 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
4Q19 - All Eyes On Countdown Clock To IND Acceptance
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap; IND Filed for Lead Drug ARCT-810; FDA Recommends Going Directly Into Patients; Raise PT to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Yas'' Weekly Recap of Our Key Notes and 19 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y